Company: PSTV
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047698
Chunk: 146

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 7
Chunk 146
---
 cash from outside sources through a combination of equity offerings, debt financings and potential collaboration, license or development agreements to fund our future clinical development programs, commercialization of CNSide, and other operations in the next twelve months from the filing of this Form 10-K. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. There can be no assurance that we will be able to continue to raise additional capital in the future. Our inability to raise additional cash would have a material adverse impact on our operations, implementation of our strategy and ability to maintain compliance with applicable requirements, including Nasdaq listing rules. 

Our present and future funding and cash requirements will depend on many factors, including, among other things: 

•the progress, timing and completion of our ongoing and planned clinical trials and nonclinical studies;

•our ability to receive, and the timing of receipt of, future regulatory approvals for our product candidates and the costs related thereto;

•the development and utility of the CNSideTM Test;

•the scope, progress, results and costs of our ongoing and planned operations;

•the costs associated with expanding our operations and building our sales and marketing capabilities;

•our ability to establish strategic collaborations; 

•the cost and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;

•the revenue, if any, received from commercial sales of our product candidates, if approved; and

•potential new product candidates that the Company identifies and attempts to develop.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to our ability to continue as a going concern.

71 

Cash (used in) provided by operating, investing, and financing activities for the year ended December 31, 2024 and 2023 is summarized as follows (in thousands): 

    Years Ended December 31,

    2024

    2023

    Net cash used in operating activities
     
    $
    (10,554
    )
     
    $
    (12,851
    )

    Net cash used